Halozyme Therapeutics Inc (HALO)

[Fred Kadiddlehopper]

Good old Jefferies:

Halozyme Therapeutics, Inc. (HALO) Given “Sell” Rating at Jefferies Group
May 11th, 2016 - 0 comments - Filed Under - by Mark Dietrich
http://www.watchlistnews.com/halozyme-therapeutics-inc-halo-given-sell-rating-at-jefferies-group/691924.html

Halozyme Therapeutics, Inc. logoJefferies Group reaffirmed their sell rating on shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in a report published on Tuesday morning, MarketBeat reports. The brokerage currently has a $6.75 price objective on the biopharmaceutical company’s stock.

Halozyme Therapeutics (NASDAQ:HALO) opened at 9.85 on Tuesday. The firm’s market capitalization is $1.26 billion. The stock’s 50 day moving average is $10.53 and its 200-day moving average is $12.20. Halozyme Therapeutics has a 1-year low of $6.96 and a 1-year high of $25.25.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.20) by $0.04. During the same quarter in the previous year, the business posted ($0.12) earnings per share. The firm had revenue of $42.50 million for the quarter, compared to the consensus estimate of $29.65 million. The firm’s quarterly revenue was up 127.3% compared to the same quarter last year. Equities research analysts forecast that Halozyme Therapeutics will post ($0.98) EPS for the current year.

A number of hedge funds have recently added to or reduced their stakes in the company. IFP Advisors Inc boosted its stake in Halozyme Therapeutics by 300.8% in the first quarter. IFP Advisors Inc now owns 11,366 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 8,530 shares during the last quarter. Woodstock purchased a new stake in Halozyme Therapeutics during the fourth quarter valued at $503,000. Franklin Street Advisors Inc. NC boosted its stake in Halozyme Therapeutics by 66.7% in the first quarter. Franklin Street Advisors Inc. NC now owns 50,000 shares of the biopharmaceutical company’s stock valued at $474,000 after buying an additional 20,000 shares during the last quarter. DekaBank Deutsche Girozentrale boosted its stake in Halozyme Therapeutics by 1.6% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 65,000 shares of the biopharmaceutical company’s stock valued at $1,132,000 after buying an additional 1,000 shares during the last quarter. Finally, Nationwide Fund Advisors boosted its stake in Halozyme Therapeutics by 2.3% in the fourth quarter. Nationwide Fund Advisors now owns 69,817 shares of the biopharmaceutical company’s stock valued at $1,210,000 after buying an additional 1,563 shares during the last quarter.

HALO has been the subject of a number of other reports. Barclays decreased their price target on Halozyme Therapeutics from $27.00 to $16.00 and set an overweight rating for the company in a research note on Wednesday, February 24th. Canaccord Genuity assumed coverage on Halozyme Therapeutics in a research note on Monday, February 1st. They issued a buy rating and a $10.00 price target for the company. JMP Securities decreased their price target on Halozyme Therapeutics from $22.00 to $20.00 and set a market outperform rating for the company in a research note on Wednesday, March 9th. Zacks Investment Research downgraded Halozyme Therapeutics from a hold rating to a sell rating in a research note on Friday, January 15th. Finally, Piper Jaffray restated an overweight rating and issued a $20.00 price target (down from $24.00) on shares of Halozyme Therapeutics in a research note on Tuesday, January 26th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. The stock presently has an average rating of Buy and an average price target of $17.64.

Halozyme Therapeutics, Inc is a biotechnology company, which is focused on developing and commercializing oncology therapies that target the tumor microenvironment. The Company’s development pipeline consists primarily of clinical-stage product candidates in oncology and diabetes. The product candidates in its pipeline are based on rHuPH20, a human recombinant hyaluronidase enzyme.